Cover Image
Market Research Report
Product code 
1030149

Cancer Pain Market by Drug Type (Opioids, Non-opioids, & Nerve Blockers), & Disease Indication (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, & Others): Global Opportunity Analysis & Industry Forecast, 2021-2030

Published: | Allied Market Research | 189 Pages | Delivery time: 2-3 business days

Price

Back to Top
Cancer Pain Market by Drug Type (Opioids, Non-opioids, & Nerve Blockers), & Disease Indication (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, & Others): Global Opportunity Analysis & Industry Forecast, 2021-2030
Published: July 1, 2021
Allied Market Research
Content info: 189 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

The global cancer pain market was valued at $6,197.8 million in 2020, and is projected to reach $10,329.4 million by 2030, growing at a CAGR of 5.3% from 2021 to 2030.

Cancer pain can be due to the disease condition itself or may be due to the associated treatments such as surgeries, chemotherapy, and other therapies or when A tumor that presses on bones, nerves, or organs can cause pain. Pain in cancer may come from compressing or infiltrating nearby body parts, from treatments and diagnostic procedures or from the skin, nerve, and the other changes caused by a hormone imbalance or immune response.

Most chronic pain is caused by the illness and most acute pain is caused by the treatment or diagnostic procedures. The radiotherapy and chemotherapy may produce painful conditions that persist long after treatment has ended. The presence of pain depends mainly on the location of cancer and the stage of the disease. At any given time with malignant cancer smacks pain. A lot of treatments are available for cancer pain. These include opioids, non-opioids, and nerve blockers.

The impact of COVID-19 pandemic is expected to remain moderate for the cancer pain market. The companies are facing a setback, owing to the lockdown, which led to a drop in the manufacturing and the patient flow reduced substantially. Also, the demand of cancer pain drugs further reduced due to the delayed shipments & production schedules which furthers create financial problems for companies with heavy debts. This, in turn, has limited the impact of COVID-19 on the cancer pain market Furthermore, as per government rules only emergency care would be provided to patient many cancer treatment and surgeries were delayed in pandemic which reduced the patients flow in cancer clinics and hospitals. . Thus, limited availability of medical care for conditions other than COVID-19 within the country has impacted the cancer pain market in a moderate manner.

There is surge in the demand for cancer pain drugs owing to the growth in incidence of different forms of cancer, higher number of R&D studies to develop cancer pain therapeutics, and increase in adoption of cancer pain drugs. In addition, growth in the geriatric population, rise in awareness related to different cancers, surge in technological advancements for cancer pain drugs, and wide availability of cancer pain drugs further drive the market growth. However, adverse effects associated with cancer pain are projected to impede the market growth. On the contrary, rise in number of pipeline drugs and growth opportunities in emerging market are estimated to create lucrative opportunities in the near future

Cancer pain market is segmented on the basis of drug type, disease indication, and region. By drug type, the market is classified as opioids, non-opioids, and nerve blockers. The opioids are further segmented into morphine, fentanyl, and others.

The non-opioids are further divided into acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs). According to the disease indication, the market is categorized into lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the key players operating in the global cancer pain market include Aoxing Pharmaceutical Company, Inc., BioDelivery Sciences International, Inc., CK Life Sciences (WEX Pharmaceuticals), Daiichi Sankyo Co., Ltd., Grunenthal Pharma GmbH & Co. KCG, Hisamitsu Pharmaceutical Co., Inc., Mundipharma International Limited, Orexo AB, Pfizer Inc. and Teva Pharmaceutical Industries Limited, Elli Lilly and Company, ProStrakan Group, Sanofi S.A, Endo Pharmaceuticals Inc, Johnson & Johnson Services, Inc. and among others.

KEY BENEFITS FOR STAKEHOLDERS

  • This report entails a detailed quantitative analysis along with the current global cancer pain market trends from 2020 to 2030 to identify the prevailing opportunities along with the strategic assessment.
  • The cancer pain market forecast is studied from 2020 to 2030.
  • The market size and estimations are based on a comprehensive analysis of key developments in the cancer pain industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the cancer pain market.

KEY MARKET SEGMENTS

By Drug Type

  • Opioids
  • Morphine
  • Fentanyl
  • Others
  • Non-opioids
  • Acetaminophen
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Nerve Blockers

By Disease Indication

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood Cancer
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  •  * Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Aoxing Pharmaceutical Company,Inc.,
  • BioDelivery Sciences International, Inc.,
  • CK Life Sciences (WEX Pharmaceuticals)
  • Daiichi Sankyo Co., Ltd.,
  • Grunenthal Pharma GmbH & Co. KCG
  • Hisamitsu Pharmaceutical Co., Inc.,
  • Mundipharma International Limited
  • Orexo AB
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited

List of other players in the value chain (profiles not included in the report):

  • Elli Lilly and Company.
  • ProStrakan Group
  • Sanofi S.A.
  • Endo Pharmaceuticals Inc
  • Johnson & Johnson Services, Inc.
Product Code: A04761

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five force analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Rise in incidence of cancer across the globe
      • 3.5.1.2.Surge in global geriatric population
      • 3.5.1.3.Increase in healthcare expenditure worldwide
    • 3.5.2.Restraint
      • 3.5.2.1.Adverse effects associated with the use of drugs employed in cancer pain management
    • 3.5.3.Opportunities
      • 3.5.3.1.Increase in number of pipeline drugs
      • 3.5.3.2.Growth opportunities in emerging markets
    • 3.5.4.Impact analyses
  • 3.6.COVID-19 impact analysis on cancer pain Market56

CHAPTER 4:CANCER PAIN MARKET, BY DRUG TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Opioids
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by type
      • 4.2.2.1.Morphine
      • 4.2.2.1.1.Market size and forecast
      • 4.2.2.2.Fentanyl
      • 4.2.2.2.1.Market size and forecast
      • 4.2.2.3.Others
      • 4.2.2.3.1.Market size and forecast
    • 4.2.3.Market size and forecast, by region
    • 4.2.4.Market analysis, by country
  • 4.3.Non-opioids
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by type
      • 4.3.2.1.Acetaminophen
      • 4.3.2.1.1.Market size and forecast
      • 4.3.2.2.Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
      • 4.3.2.2.1.Market size and forecast
    • 4.3.3.Market size and forecast, by region
    • 4.3.4.Market analysis, by country
  • 4.4.Nerve blockers
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country

CHAPTER 5:CANCER PAIN MARKET, BY DISEASE INDICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Lung cancer
    • 5.2.1.Market size and forecast
    • 5.2.2.Market analysis, by country
  • 5.3.Colorectal cancer
    • 5.3.1.Market size and forecast
    • 5.3.2.Market analysis, by country
  • 5.4.Breast cancer
    • 5.4.1.Market size and forecast
    • 5.4.2.Market analysis, by country
  • 5.5.Prostate cancer
    • 5.5.1.Market size and forecast
    • 5.5.2.Market analysis, by country
  • 5.6.Blood cancer
    • 5.6.1.Market size and forecast
    • 5.6.2.Market analysis, by country
  • 5.7.Others
    • 5.7.1.Market size and forecast
    • 5.7.2.Market analysis, by country

CHAPTER 6:CANCER PAIN MARKET, BY REGION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.North America
    • 6.2.1.Key market trends, growth factors, and opportunities
    • 6.2.2.Market size and forecast, by country
      • 6.2.2.1.U.S.
      • 6.2.2.1.1.U.S. market size and forecast, by type
      • 6.2.2.1.2.U.S. market size and forecast, by disease indication
      • 6.2.2.2.Canada
      • 6.2.2.2.1.Canada market size and forecast, by type
      • 6.2.2.2.2.Canada market size and forecast, by disease indication
      • 6.2.2.3.Mexico
      • 6.2.2.3.1.Mexico market size and forecast, by type
      • 6.2.2.3.2.Mexico market size and forecast, by disease indication
    • 6.2.3.Market size and forecast, by type
    • 6.2.4.Market size and forecast, by disease indication
  • 6.3.Europe
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Market size and forecast, by country
      • 6.3.2.1.Germany
      • 6.3.2.1.1.Germany market size and forecast, by type
      • 6.3.2.1.2.Germany market size and forecast, by disease indication
      • 6.3.2.2.France
      • 6.3.2.2.1.France market size and forecast, by type
      • 6.3.2.2.2.France market size and forecast, by disease indication
      • 6.3.2.3.UK
      • 6.3.2.3.1.UK market size and forecast, by type
      • 6.3.2.3.2.UK market size and forecast, by disease indication
      • 6.3.2.4.Italy
      • 6.3.2.4.1.Italy market size and forecast, by type
      • 6.3.2.4.2.Italy market size and forecast, by disease indication
      • 6.3.2.5.Spain
      • 6.3.2.5.1.Spain market size and forecast, by type
      • 6.3.2.5.2.Spain market size and forecast, by disease indication
      • 6.3.2.6.Rest of Europe
      • 6.3.2.6.1.Rest of Europe market size and forecast, by type
      • 6.3.2.6.2.Rest of Europe market size and forecast, by disease indication
    • 6.3.3.Market size and forecast, by type
    • 6.3.4.Market size and forecast, by disease indication
  • 6.4.Asia-Pacific
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Market size and forecast, by country
      • 6.4.2.1.Japan
      • 6.4.2.1.1.Japan market size and forecast, by type
      • 6.4.2.1.2.Japan market size and forecast, by disease indication
      • 6.4.2.2.China
      • 6.4.2.2.1.China market size and forecast, by type
      • 6.4.2.2.2.China market size and forecast, by disease indication
      • 6.4.2.3.Australia
      • 6.4.2.3.1.Australia market size and forecast, by type
      • 6.4.2.3.2.Australia market size and forecast, by disease indication
      • 6.4.2.4.India
      • 6.4.2.4.1.India market size and forecast, by type
      • 6.4.2.4.2.India market size and forecast, by disease indication
      • 6.4.2.5.Rest of Asia-Pacific
      • 6.4.2.5.1.Rest of Asia- Pacific market size and forecast, by type
      • 6.4.2.5.2.Rest of Asia- Pacific market size and forecast, by disease indication
    • 6.4.3.Market size and forecast, by type
    • 6.4.4.Market size and forecast, by disease indication
  • 6.5.LAMEA141
    • 6.5.1.Key market trends, growth factors, and opportunities
    • 6.5.2.Market size and forecast, by country
      • 6.5.2.1.Brazil
      • 6.5.2.1.1.Brazil market size and forecast, by type
      • 6.5.2.1.2.Brazil market size and forecast, by disease indication
      • 6.5.2.2.Saudi Arabia
      • 6.5.2.2.1.Saudi Arabia market size and forecast, by type
      • 6.5.2.2.2.Saudi Arabia market size and forecast, by disease indication
      • 6.5.2.3.South Africa
      • 6.5.2.3.1.South Africa market size and forecast, by type
      • 6.5.2.3.2.South Africa market size and forecast, by disease indication
      • 6.5.2.4.Rest of LAMEA
      • 6.5.2.4.1.Rest of LAMEA market size and forecast, by type
      • 6.5.2.4.2.Rest of LAMEA market size and forecast, by disease indication
    • 6.5.3.Market size and forecast, by type
    • 6.5.4.Market volume and forecast, by disease indication

CHAPTER 7:COMPANY PROFILES153

  • 7.1.AOXING PHARMACEUTICAL COMPANY, INC.
    • 7.1.1.Company overview
    • 7.1.2.Company snapshot
    • 7.1.3.Operating business segments
    • 7.1.4.Product Portfolio
  • 7.2.BIODELIVERY SCIENCES INTERNATIONAL, INC.
    • 7.2.1.Company overview
    • 7.2.2.Company snapshot
    • 7.2.3.Operating business segments
    • 7.2.4.Product Portfolio
    • 7.2.5.Business performance
    • 7.2.6.Key strategic moves and developments
  • 7.3.CK LIFE SCIENCES (WEX PHARMACEUTICALS).
    • 7.3.1.Company overview
    • 7.3.2.Company snapshot
    • 7.3.3.Operating business segments
    • 7.3.4.Product Portfolio
    • 7.3.5.Business performance
  • 7.4.DAIICHI SANKYO CO., LTD.
    • 7.4.1.Company overview
    • 7.4.2.Company snapshot
    • 7.4.3.Operating business segments
    • 7.4.4.Product Portfolio
    • 7.4.5.Business performance
    • 7.4.6.Key strategic moves and developments
  • 7.5.GRUNENTHAL PHARMA GmbH & CO. KG
    • 7.5.1.Company overview
    • 7.5.2.Company snapshot
    • 7.5.3.Product Portfolio
    • 7.5.4.Key strategic moves and developments
  • 7.6.HISAMITSU PHARMACEUTICAL CO., INC.
    • 7.6.1.Company overview
    • 7.6.2.Company snapshot
    • 7.6.3.Operating business segments
    • 7.6.4.Product portfolio
    • 7.6.5.Business performance
    • 7.6.6.Key strategic moves and developments
  • 7.7.MUNDIPHARMA INTERNATIONAL LIMITED
    • 7.7.1.Company overview
    • 7.7.2.Company snapshot
    • 7.7.3.Product Portfolio
    • 7.7.4.Key strategic moves and developments
  • 7.8.OREXO AB
    • 7.8.1.Company overview
    • 7.8.2.Company snapshot
    • 7.8.3.Operating business segments
    • 7.8.4.Product Portfolio
    • 7.8.5.Business performance
  • 7.9.PFIZER INC.
    • 7.9.1.Company overview
    • 7.9.2.Company snapshot
    • 7.9.3.Operating business segments
    • 7.9.4.Product Portfolio
    • 7.9.5.Business performance
  • 7.10.TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    • 7.10.1.Company overview
    • 7.10.2.Company snapshot
    • 7.10.3.Operating business segments
    • 7.10.4.Product Portfolio
    • 7.10.5.Business performance

LIST OF TABLES

  • TABLE 01.GLOBAL CANCER PAIN MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
  • TABLE 02.OPIOIDS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 03.OPIOIDS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 04.NON-OPIOIDS MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 05.NON-OPIOIDS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 06.NERVE BLOCKERS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 07.GLOBAL CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 08.LUNG CANCER PAIN MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.COLORECTAL CANCER PAIN MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.BREAST CANCER PAIN MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.PROSTATE CANCER PAIN MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12.BLOOD CANCER PAIN MARKET, BY REGION, 2020-2030 ($MILLION)92
  • TABLE 13.CANCER PAIN MARKET FOR OTHER DISEASE INDICATION, BY REGION, 2017-2025 ($MILLION)
  • TABLE 14.CANCER PAIN MARKET REVENUE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.NORTH AMERICA CANCER PAIN MARKET REVENUE, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 16.U.S. CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)1
  • TABLE 17.U.S. CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 18.CANADA CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 19.CANADA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 20.MEXICO CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 21.MEXICO CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 22.NORTH AMERICA CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 23.NORTH AMERICA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 24.EUROPE CANCER PAIN MARKET REVENUE, BY COUNTRY, 2021-2030 ($MILLION)
  • TABLE 25.GERMANY CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 26.GERMANY CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 27.FRANCE CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 28.FRANCE CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 29.UK CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 30.UK CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 31.ITALY CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 32.ITALY CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 33.SPAIN CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 34.SPAIN CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 35.REST OF EUROPE CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 36.REST OF EUROPE CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 37.EUROPE CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 38.EUROPE CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 39.ASIA-PACIFIC CANCER PAIN MARKET REVENUE, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 40.JAPAN CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 41.JAPAN CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 42.CHINA CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 43.CHINA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 44.AUSTRALIA CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 45.AUSTRALIA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 46.INDIA CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 47.INDIA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 48.REST OF ASIA-PACIFIC CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 49.REST OF ASIA-PACIFIC CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 50.ASIA-PACIFIC CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 51.ASIA-PACIFIC CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 52.LAMEA CANCER PAIN MARKET REVENUE, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 53.BRAZIL CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 54.BRAZIL CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 55.SAUDI ARABIA CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 56.SAUDI ARABIA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 57.SOUTH AFRICA CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 58.SOUTH AFRICA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 59.REST OF LAMEA CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 60.REST OF LAMEA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 61.LAMEA CANCER PAIN MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 62.LAMEA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020-2030 ($MILLION)
  • TABLE 63.AOXING PHARM: COMPANY SNAPSHOT
  • TABLE 64.AOXING PHARM: OPERATING SEGMENTS
  • TABLE 65.AOXING PHARM: PRODUCT PORTFOLIO
  • TABLE 66.BDSI: COMPANY SNAPSHOT
  • TABLE 67.BDSI: OPERATING SEGMENTS
  • TABLE 68.BDSI: PRODUCT PORTFOLIO
  • TABLE 69.CK LIFE SCIENCES: COMPANY SNAPSHOT
  • TABLE 70.CK LIFESCIENCES: OPERATING SEGMENTS
  • TABLE 71.CK LIFESCIENCES: PRODUCT PORTFOLIO
  • TABLE 72.DAIICHI SANKYO: COMPANY SNAPSHOT
  • TABLE 73.DAIICHI SANKYO: OPERATING SEGMENTS
  • TABLE 74.DAIICHI SANKYO: PRODUCT PORTFOLIO
  • TABLE 75.GRUNENTHAL: COMPANY SNAPSHOT
  • TABLE 76.GRUNENTHAL: PRODUCT PORTFOLIO
  • TABLE 77.HISAMITSU PHARMACEUTICAL: COMPANY SNAPSHOT
  • TABLE 78.HISAMITSU PHARMACEUTICAL: OPERATING SEGMENTS
  • TABLE 79.HISAMITSU PHARMACEUTICAL: PRODUCT PORTFOLIO
  • TABLE 80.MUNDIPHARMA: COMPANY SNAPSHOT
  • TABLE 81.MUNDIPHARMA: PRODUCT PORTFOLIO
  • TABLE 82.OREXO: COMPANY SNAPSHOT
  • TABLE 83.OREXO: OPERATING SEGMENTS
  • TABLE 84.OREXO: PRODUCT PORTFOLIO
  • TABLE 85.PFIZER: COMPANY SNAPSHOT
  • TABLE 86.PFIZER: OPERATING SEGMENTS
  • TABLE 87.PFIZER: PRODUCT PORTFOLIO
  • TABLE 88.TEVA: COMPANY SNAPSHOT
  • TABLE 89.TEVA: OPERATING SEGMENTS
  • TABLE 90.TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.CANCER PAIN MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
  • FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.HIGH THREAT OF SUBSTITUTES
  • FIGURE 09.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 10.HIGH INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2020
  • FIGURE 12.IMPACT ANALYSES
  • FIGURE 13.MORPHINE MARKET FOR CANCER PAIN, 2020-2030 ($MILLION)
  • FIGURE 14.FENTANYL MARKET FOR CANCER PAIN, 2020-2030 ($MILLION)
  • FIGURE 15.OTHERS MARKET FOR CANCER PAIN, 2020-2030 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF OPIOIDS MARKET, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 17.ACETAMINOPHEN MARKET FOR CANCER PAIN, 2020-2030 ($MILLION)
  • FIGURE 18.NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR CANCER PAIN, 2020-2030 ($MILLION)
  • FIGURE 19.COMPARATIVE ANALYSIS OF NON-OPIOIDS, MARKET, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF NERVE BLOCKERS MARKET, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF LUNG CANCER PAIN MARKET, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 22.COMPARATIVE ANALYSIS OF COLORECTAL CANCER PAIN MARKET, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 23.COMPARATIVE ANALYSIS OF BREAST CANCER PAIN MARKET, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 24.COMPARATIVE ANALYSIS OF PROSTATE CANCER PAIN MARKET, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 25.COMPARATIVE ANALYSIS OF BLOOD CANCER PAIN MARKET, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 26.COMPARATIVE ANALYSIS OF CANCER PAIN MARKET FOR OTHER INDICATION MARKET, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 27.BDSI: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 28.CK LIFE SCIENCES: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 29.CK LIFE SCIENCES: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 30.CK LIFE SCIENCES: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 31.DACIIHI SANKYO: NET SALES, 2019-2021 ($MILLION)1
  • FIGURE 32.DAIICHI SANKYO: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 33.HISAMITSU PHARMACEUTICAL REVENUE, 2017-2019 ($MILLION)
  • FIGURE 34.HISAMITSU PHARMACEUTICAL: REVENUE SHARE BY BUSINESS SEGMENT, 2020 (%)
  • FIGURE 35.HISAMITSU PHARMACEUTICAL: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 36.OREXO: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 37.OREXO: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 38.OREXO: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 39.PFIZER: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 40.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 41.PFIZER: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 42.TEVA: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 43.TEVA: REVENUE SHARE BY REGION, 2020 (%)